Hemostatic Agents Market Report 2026

Hemostatic Agents Market Overview

• Hemostatic Agents market size has reached to $4.42 billion in 2025 • Expected to grow to $5.71 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Rise In Surgical Procedures Fueling The Growth Of The Market Due To Increasing Demand For Bleeding Control In Operative Settings • Market Trend: Next-Generation Collagen-Based Hemostatic Pad Enhances Surgical Efficiency And Patient Safety • North America was the largest region in 2025.

What Is Covered Under Hemostatic Agents Market?

Hemostatic agents are specialized substances designed to support the body's natural process of blood clotting by helping to control and stop bleeding. These agents function by interacting with various components of the coagulation system to facilitate the formation of a stable clot at the site of vascular injury. The main types of hemostatic agents include thrombin-based hemostats, gelatin-based hemostats, collagen-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, fibrin sealants, and others. Thrombin-based hemostats utilize thrombin, a natural blood enzyme, to rapidly stop bleeding by encouraging clot formation. It is applied for trauma, cardiovascular surgery, general surgery, plastic surgery, orthopedic surgery, neurosurgery, and others by several end-users, including hospitals, surgery centers, nursing homes, and others.

What Is The Hemostatic Agents Market Growth Forecast?

The hemostatic agents market size is expected to see strong growth in the next few years. It will grow to $5.71 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of recombinant and sprayable fibrin sealants, expansion in minimally invasive and orthopedic surgeries, rising demand for multi-agent and combination hemostats, increased adoption in plastic and neurosurgery applications, regulatory emphasis on sterility and biocompatibility. Major trends in the forecast period include rising demand for advanced hemostatic agents in surgical procedures, increasing adoption of combination and multi-agent hemostats, growth in fibrin sealants and biologically derived products, expansion of hemostats use in trauma and cardiovascular surgeries, enhanced focus on safety, sterility, and regulatory compliance.

Global Hemostatic Agents Market Segmentation

1) By Type: Thrombin-Based Hemostats, Gelatin-Based Hemostats, Collagen-Based Hemostats, Oxidized Regenerated Cellulose-Based Hemostats, Combination Hemostats, Fibrin Sealants, Other Types 2) By Application: Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, Other Applications 3) By End-User: Hospitals, Surgery Centers, Nursing Homes, Other End Users Subsegments: 1) By Thrombin-Based Hemostats: Bovine Thrombin, Human Thrombin, Poxidized Regenerated Cellulose (Orc)Ine Thrombin, Combined Thrombin Products 2) By Gelatin-Based Hemostats: Absorbable Gelatin Sponges, Gelatin Powder, Gelatin Paste, Gelatin With Thrombin 3) By Collagen-Based Hemostats: Collagen Sponges, Collagen Powder, Collagen With Thrombin, Collagen Sheets Or Patches 4) By Oxidized Regenerated Cellulose-Based Hemostats: Oxidized Regenerated Cellulose (ORC) Pads, Oxidized Regenerated Cellulose (ORC) Mesh, Oxidized Regenerated Cellulose (ORC) Powder, Oxidized Regenerated Cellulose (ORC) With Other Active Agents 5) By Combination Hemostats: Gelatin And Thrombin Combinations, Collagen And Thrombin Combinations, Oxidized Regenerated Cellulose (ORC) And Thrombin Combinations, Multi-Agent Combinations 6) By Fibrin Sealants: Human Plasma-Derived Fibrin Sealants, Recombinant Fibrin Sealants, Sprayable Fibrin Sealants, Liquid Fibrin Sealants, Fibrin Sealants With Antimicrobials 7) By Other Types: Polysaccharide-Based Hemostats, Synthetic Polymer-Based Hemostats, Microfibrillar Collagen Hemostats, Chitosan-Based Hemostats, Calcium-Based Hemostats

What Is The Driver Of The Hemostatic Agents Market?

The increasing number of surgical procedures is expected to propel the growth of the hemostatic agents market going forward. Surgical procedures are medical operations performed by healthcare professionals using specialized instruments to address, repair, or remove parts of the body for health-related purposes. The rise in surgical procedures is largely attributed to the increasing number of chronic conditions, which often demand surgical intervention to manage health issues and improve patient outcomes. Hemostatic agents are important in surgeries, as they help stop bleeding quickly, reducing blood loss and improving visibility in the surgical area for more accurate work. For instance, in October 2025, according to the UK Health Security Agency (UKHSA), a UK-based national government public health agency, surveillance data from the 2023–24 period showed that 135,619 operations were submitted with 1,276 surgical site infections (SSIs) detected during inpatient stay or upon readmission, representing an 8.4% increase in submissions compared to the previous year. Therefore, the increasing number of surgical procedures is driving the growth of the hemostatic agents industry.

Key Players In The Global Hemostatic Agents Market

Major companies operating in the hemostatic agents market are Pfizer Inc., Johnson & Johnson Services Inc., Becton Dickinson & Co., CSL Ltd., Baxter International Inc., Teleflex Inc., Integra LifeSciences Holdings Corp., Gelita Medical, Artivion Inc., B. Braun Melsungen AG, Advanced Medical Solutions Group Plc, Z‑Medica, Marine Polymer Technologies Inc., MedTrade Products Ltd., Samyang Holdings Corp., Vascular Solutions Pc, BioCer Entwicklungs GmbH, Starch Medical Inc., Arch Therapeutics Inc., Medcura Inc., Biom’Up SAS.

Global Hemostatic Agents Market Trends and Insights

Major companies operating in the hemostatic agents market are focusing on developing advanced solutions, such as collagen-based hemostats, to offer rapid and effective hemostasis and tissue sealing for both open and minimally invasive surgeries. Collagen-based hemostats are hemostatic materials derived from purified collagen that assist in stopping bleeding by enhancing the body’s natural clotting process at the site of a wound or surgical incision. For instance, in March 2025, Baxter, a US-based healthcare company, launched HEMOPATCH Sealing Hemostat, a collagen-based absorbable pad. This advanced collagen-based pad incorporates a dual-action system combining a collagen matrix with an NHS-PEG layer that forms a hydrogel upon contact with moisture, enabling quick sealing of bleeding sites. It provides strong adhesion to wet tissues, making it suitable for both open and minimally invasive surgeries where other agents may be less effective. The patch delivers hemostasis in under two minutes without the need for temperature-controlled storage or special preparation, streamlining surgical procedures. It also naturally dissolves in the body within 6 to 8 weeks and can be stored at room temperature for up to three years, addressing important clinical and storage requirements.

What Are Latest Mergers And Acquisitions In The Hemostatic Agents Market?

In May 2025, Merit Medical Systems Inc., a US-based medical device company, acquired Biolife Delaware LLC for an undisclosed amount. Following the acquisition, Merit is positioned to deliver a broader selection of products that help streamline and improve consistency in post-procedure care. The deal also enhances Merit's capabilities with unique hemostatic solutions suited for diverse clinical uses, such as managing bleeding from vascular closures and indwelling catheters. Biolife Delaware LLC is a US-based manufacturer of hemostatic agents.

Regional Outlook

North America was the largest region in the hemostatic agents market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Hemostatic Agents Market?

The hemostatic agents market consists of sales of chitosan-based hemostats, flowable hemostats, synthetic polymer-based hemostats, topical absorbable hemostats, and adhesive hemostatic films. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.